Some ethical considerations for the "off-label" use of drugs such as Avastin.
Wong
D
D
St Paul's Eye Unit, Royal Liverpool University Trust Hospital, Liverpool, UK. shdwong@liv.ac.uk
Kyle
G
G
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D017277:Drug Approval; D011307:Drug Prescriptions; D004358:Drug Therapy / Q000941:ethics; D026690:Ethics, Clinical; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy*; D028701:Patient Rights; D016032:Randomized Controlled Trials as Topic / Q000941:ethics; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab